

The prognostic significance of different proportion of signet-ring cells of colorectal carcinoma

Wei Chen^{1†}, Huajun Cai^{2†}, Kui Chen^{3†}, Xing Liu², Weizhong Jiang⁴, Shoufeng Li⁴, Yiyi Zhang², Zhifen Chen⁴, Guoxian Guan^{2*}

ABSTRACT

While the prognosis of patients with partial signet-ring cell carcinoma (PSRCC) has been rarely reported, colorectal signet-ring cell carcinoma (SRCC) has been associated with poor prognosis. The aim of this study was to analyze the prognosis of patients with different signet-ring cell (SRC) composition and establish a prediction model. A total of 91 patients with SRC component were included in the study. These patients were divided into two groups: SRCC group (SRC composition >50%; n = 41) and PSRCC group (SRC composition ≤50%; n = 50). COX regression model was used to identify independent prognostic factors for overall survival (OS). A predictive nomogram was established and compared with the 7th American Joint Committee on Cancer (AJCC) staging system. After a median follow-up of 16 months, no significant difference in OS was observed in either group. Pre-operative carcinoembryonic antigen level, pN stage, M stage, pre-operative ileus, and adjuvant chemotherapy were independent prognostic risk factors for OS ($p < 0.05$). A nomogram for predicting the OS of colorectal SRCC was established with a C-index of 0.800, and it showed better performance than that of the 7th AJCC staging system ($p < 0.001$). In summary, the ratio of SRC component was not an independent prognostic factor of the OS. Those patients with <50% of SRC component should be given the same clinical attention. A predictive nomogram for survival based on five independent prognostic factors was developed and showed better performance than the 7th AJCC staging system. This resulted to be helpful for individualized prognosis prediction and risk assessment.

KEYWORDS: Rectal cancer; signet-ring cell carcinoma; prognosis; nomogram

INTRODUCTION

Signet-ring cell carcinoma (SRCC) is a rare histological subtype of colorectal cancer (CRC), which was first reported by Laufman and Saphir in 1951 [1]. According to the World Health Organization (WHO) criterion, SRCC is composed of more than 50% of signet-ring cells (SRCs) in which the nucleus

is squeezed to the side by the prominent intracytoplasmic mucin [2]. The overall incidence of SRCC in colorectum is rare, ranging from 0.1% to 5% in Western countries [3-6] and 1.2-4.6% in China [7]. When compared with classical adenocarcinoma, SRCC is more likely to be associated with younger age at presentation, more advanced stage of diagnosis, and worse prognosis. Due to its rare occurrence, literature on colorectal SRCC is limited. However, distinct differences in clinicopathological manifestations make SRCC a unique entity that requires special attention.

Eventhough, the WHO defines SRCC as SRC that exceeds 50% of tumor tissue composition, in the daily clinical practice, we also encounter patients with tumors exhibiting a component of SRCs with less than 50% of the tumor mass. However, the clinical characteristics and prognosis of these patients are less well characterized, mainly due to the overall low incidence of colorectal SRCC. Whether the ratio of SRCs component plays a role in tumor biology and prognosis in SRCC still remains uncertain. The high-risk patients could be candidates for more individualized follow-up and intense adjuvant therapy. In addition, no individualized prognostic prediction model has yet been established for this subset of patients.

Therefore, the present study was aimed to compare the clinicopathological characteristics and prognosis of CRC patients with different SRC components, and to identify independent prognostic factors. Moreover, an individualized predicting model for the prognosis of CRC patients with different

¹Department of Gynecology, The Affiliated Hospital of Putian University, Putian, China

²Department of Colorectal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China

³Department of General Surgery, The First Hospital of Fuzhou City Affiliated Fujian Medical University, Fuzhou, China

⁴Department of Colorectal Surgery, Fujian Medical University Union Hospital, Fuzhou, China

*Corresponding authors: Guoxian Guan, Department of Colorectal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. E-mail: fjhggx@163.com

†These authors contributed equally to this work.

DOI: <https://dx.doi.org/10.17305/bjbms.2021.5856>

Submitted: 30 March 2021/Accepted: 16 May 2021/

Published Online: 29 May 2021

Conflicts of interest statement: The authors declare no conflicts of interest

Funding: This study was supported by the National Clinical Key Specialty Construction Project (General Surgery) of China (NO.2012-649), Science Foundation of the Fujian Province (NO.2016J01602), Special Financial Foundation of Fujian Province (NO.2015-1297), Young and Middle-aged backbone training project in the health system of Fujian Province (NO.2016-ZQN-26) and Professor Development Foundation of Fujian Medical University (NO.JS11006).



©The Author(s) (2022). This work is licensed under a Creative Commons Attribution 4.0 International License

SRC component was established to help better prognostication and clinical decision-making.

MATERIALS AND METHODS

Patients

Clinicopathological data of patients with colorectal SRCC at Fujian Medical University Union Hospital from January 2010 to September 2018 were analyzed retrospectively. The inclusion criteria were as follows: (1) Pathologically proven SRCC; (2) surgical treatment, including radical and palliative surgery; and (3) complete clinical and pathological data. Exclusion criteria included (1) familial polyposis, ulcerative colitis, or Lynch syndrome; (2) multiple primary CRC or combined with other tumors; and (3) presence of other pathological components (e.g. neuroendocrine). Finally, a total of 91 patients were enrolled in our analysis.

Definitions

Patients were divided into two groups according to the percentages of SRCC and mucin: (1) SRCC group (SRC component >50%, Figure 1A) and (2) PSRCC group (SRC component ≤50%, Figure 1B). The pathological type and signet-ring cell amount and percentage were assessed by two experienced pathologists, independently. Pathological staging of the tumor was based on the 7th edition of the American Joint Committee on Cancer (AJCC) tumor staging system. Tumor location was divided into proximal colon, distal colon, and rectum. Proximal colon was defined as ileocecum, cecum, ascending colon, and transverse colon up to the hepatic flexure. Distal colon was defined as splenic flexure, descending colon, sigmoid, and rectosigmoid colon. Palliative surgery included microscopical tumor remnants (R1) and macroscopical tumor remnants (R2) resection, bypass surgery, or ileostomy.

Follow-up

All patients were followed up by an outpatient visit, telephone interview, WeChat, or email. The follow-up interval was once every 3 months in the first 2 years, once every 6 months in the following 3 years, and once a year thereafter. At each visit, all patients received imaging and laboratory examination, including tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA199). In addition, chest radiographs, computed tomography or magnetic resonance imaging examinations, and endoscopy were performed at least once a year. Further assessment, such as positron emission tomography, was performed when required. The last follow-up date was September 30, 2018. Overall survival (OS)




FIGURE 1. (A) SRCC (hematoxylin and eosin; ×200). (B) PSRCC. Signet-ring cells accounted for ≤50% of tumor composition (hematoxylin and eosin; ×200). SRCC: Signet-ring cell carcinoma; PSRCC: Partial signet-ring cell carcinoma.

was measured as the time from the date of operation to the date of death or last contact.

Statistical analysis

Statistical analysis was performed using SPSS 22.0 (SPSS INC., Chicago). Categorical variables were compared by Chi-square or Fisher's exact test. Continuous variables were compared by independent samples *t*-test. The survival rate was evaluated by the Kaplan–Meier method and compared by the log-rank test. Univariate and multivariate analysis of the independent prognostic factors of CRC with SRCC was performed using COX risk regression. Based on the independent prognostic factors in the COX regression model, a predicting nomogram was formulated using R 3.5.1 (www.r-project.org) with the survival and rms package. The discrimination of the nomogram was evaluated by calculating the Harrell's concordance index (C-index). The higher C-index the better performance of the prediction model. The nomogram was internally validated by 1000 resampling bootstrap. The calibration plot was performed by comparing the predicted survival probability and the actual observation. According to the nomogram, the total score for each patient was calculated, and the first 75% of the score was identified as cutoff value using the quartile spacing method. Risk classifications were illustrated with the Kaplan–Meier curve after the patients were divided into different prognostic groups according to percentile scores. The former 75% of the patients were classified as the low-risk group, the remaining patients as the high-risk group. To evaluate the predictive performance of the 7th AJCC staging system and our prediction model, the receiver operating characteristic (ROC) curve was drawn and the area under the ROC curve (AUC) was calculated. *p* < 0.05 was considered statistically significant.

RESULTS

Patient and pathological characteristics

A total of 91 patients with colorectal SRCC were enrolled in our analysis, including 41 patients with SRCC and

TABLE 1. Clinicopathological characteristics of SRCC colorectal cancer patients

Variables	Total (n=91)	SRCC (n=41)	PSRCC (n=50)	<i>p</i> value*
Age (years)	52.3±17.4	46.5±16.3	57±17.1	
≤40	21 (23.1)	12 (29.3)	9 (18)	0.204
>40	70 (76.9)	29 (70.7)	41 (82)	
Gender				
Male	53 (58.2)	26 (63.4)	27 (54)	0.365
Female	38 (41.8)	15 (36.6)	23 (46)	
Pre-ALB (g/l)	38.49 (7.10)	39.18 7.66)	37.92 (6.62)	0.401
Pre-CEA (ng/mL)				
≤5	53 (58.2)	29 (70.7)	24 (48)	0.029
>5	38 (41.8)	12 (29.3)	26 (52)	
Pre-CA199 (U/mL)				
≤37	64 (70.3)	34 (82.9)	30 (60)	0.017
>37	27 (29.7)	7 (17.1)	20 (40)	
Location				
Proximal colon	29 (31.9)	9 (22)	20 (40)	0.165
Distal colon	25 (27.5)	12 (29.3)	13 (26)	
Rectum	37 (40.7)	20 (48.7)	17 (34)	
Top grid	6.1±2.2	6.1±2.1	6.1±2.3	0.455
Pathological type				
Ulcer	52 (57.1)	23 (59)	29 (58)	0.495
Expanding	18 (19.8)	6 (15.4)	12 (24)	
Infiltrating	19 (20.9)	10 (25.6)	9 (18)	
pT stage				
1	2 (2.2)	1 (2.6)	1 (2.0)	0.557
2	1 (1.1)	1 (2.6)	0 (0)	
3	47 (51.6)	18 (46.2)	29 (58)	
4	39 (42.9)	19 (48.7)	20 (40)	
x				
pN stage				
0	11 (12.1)	3 (7.7)	8 (16)	0.470
1	15 (16.5)	6 (15.4)	9 (18)	
2	63 (69.2)	30 (76.9)	33 (66)	
x				
M stage				
0	65 (71.4)	27 (65.9)	38 (76)	0.286
1	26 (28.6)	14 (34.1)	12 (24)	
Neural invasion	26 (28.6)	11 (28.2)	15 (30)	0.853
Lymphovascular invasion	34 (37.4)	12 (30.8)	22 (44)	0.202
Pre-operative ileus	24 (26.4)	17 (41.5)	7 (14)	<0.003
Emergency operation	6 (6.6)	3 (7.3)	3 (6)	1
Pathological stage				
I-II	11 (12.1)	3 (7.3)	8 (16)	0.333
III-IV	80 (87.9)	38 (92.7)	42 (84)	
Surgical resection				
Radical excision	73 (80.2)	31 (75.6)	42 (84)	0.317
Palliative resection	18 (19.8)	10 (24.4)	8 (16)	
Surgical type				
Laparoscope	52 (57.1)	22 (53.7)	30 (60)	0.543
Open	39 (42.9)	19 (46.3)	20 (40)	
Adjuvant chemotherapy	73 (80.2)	33 (80.5)	40 (80)	0.954

Data are expressed as n (%) or as median±standard deviation, where appropriate. Row percentages are presented. Significant differences are bolded. **p* value resulted from comparison between SRCC and PSRCC groups. SRCC: Signet-ring cell carcinoma; PSRCC, Partial signet-ring cell carcinoma; Pre-ALB: Pre-operative albumin; Pre-CEA: Pre-operative carcinoembryonic antigen; CA199: Pre-operative carbohydrate antigen 199
P values in bold are significant

50 patients with PSRCC. There were 53 (58.2%) males and 38 (41.8%) females with a median age of 52.3 years. The clinicopathological characteristics of the two groups are shown in Table 1. No significant difference was observed between the two groups in terms of age, sex, tumor location, and pathological stage (all *p* > 0.05, Table 1). Among them, 54/91 (59.3%) patients had tumors located in the colon, while 37/91 (40.7%) had tumors located in the rectum. The distribution of sites for primary tumors was similar in SRCC and PSRCC groups (*p* = 0.165). Patients in both groups presented with larger tumors (6.1 ± 2.1 vs. 6.1 ± 2.2, *p* = 0.455) and mostly ulcerative lesion (59% vs. 58%, *p* = 0.495). Patients in the PSRCC group were more likely to present with higher pre-operative CEA and CA199 levels, when compared with SRCC patients (*p* = 0.029 and *p* = 0.017, respectively). Interestingly, we observed a higher probability of pre-operative ileus in patients in the SRCC group (41.5% vs. 14%, *p* < 0.003). A higher proportion of patients with pT3-4 (86/91, 94.5%), pN2 (63/91, 69.2%), and III-IV stage (80/91, 87.9%) disease was noted in our study cohort. There was no significant difference in pT stage, pN stage, and pathological staging between the two groups (all *p* > 0.05).

Survival outcomes

The median follow-up time was 16 months (range 1-107). In our study cohort, 52/91 (57.1%) patients experienced tumor recurrence, including peritoneal metastases (33/91, 36.3%). The 1-, 2-, and 3-year OS rates in SRCC and PSRCC group were 73.8% versus 77.4%, 48.6% versus 66.3%, and 37.4% versus 51.2%, respectively. However, this difference was not statistically significant, as demonstrated in the Kaplan–Meier survival curve (*p* = 0.409, Figure 2).




FIGURE 2. Overall survival between SRCC and PSRCC group. SRCC: Signet-ring cell carcinoma; PSRCC: Partial signet-ring cell carcinoma.

Prognostic factors of OS

Univariate analysis showed that the prognostic risk factors of OS included pre-operative CEA level (hazard ratio [HR] = 2.278, 95% confidence interval [CI] 1.269-4.090, $p = 0.006$), pre-operative albumin level (HR = 0.929, 95% CI 0.891-0.969, $p = 0.001$), tumor size (HR = 1.273, 95% CI 1.072-1.427, $p = 0.004$), pT stage (HR = 2.170, 95% CI 1.236-3.811, $p = 0.007$), pN stage (HR = 2.204, 95% CI 1.185-4.099, $p = 0.013$), pM stage (HR = 2.475, 95% CI 1.376-4.453, $p = 0.002$), pre-operative ileus (HR = 4.394, 95% CI 2.334-8.276, $p = 0.000$), emergency surgery (HR = 7.564, 95% CI 3.016-18.975, $p < 0.001$), surgical resection (HR = 2.308, 95% CI 1.223-4.356, $P = 0.010$), surgical type (HR = 2.428, 95% CI 1.345-4.382, $p = 0.003$), and adjuvant chemotherapy (HR = 0.496, 95% CI 0.251-0.981, $p = 0.004$), as shown in Table 2.

After adjusting for confounding factors, COX regression analysis demonstrated that the independent risk factors for overall survival were pre-operative CEA level (HR = 3.286, 95% CI 1.584-6.819, $p = 0.001$), pN stage (HR = 2.618, 95% CI 1.282-5.345, $p = 0.008$), M stage (HR = 2.804, 95% CI 1.165-6.747, $p = 0.021$), pre-operative ileus (HR = 5.457, 95% CI 2.142-13.900, $p < 0.001$), and adjuvant chemotherapy (HR = 0.153, 95% CI 0.064-0.362, $p < 0.001$), as demonstrated in Table 3.

TABLE 2. Univariate analysis of risk factors of OS in SRCC colorectal cancer

Variables	Unadjusted HR	95% CI	<i>P</i> value
Age (>40 years vs. ≤40 years)	0.625	0.333-1.173	0.143
Gender (female vs. male)	1.179	0.651-2.133	0.587
Pre-CEA (>5 ng/mL vs. ≤5 ng/mL)	2.278	1.269-4.090	0.006
Pre-CA199 (>37 U/mL vs. ≤37 U/mL)	1.739	0.966-3.128	0.065
Pre-ALB level	0.929	0.891-0.969	0.001
Tumor size	1.237	1.072-1.427	0.004
Location	0.851	0.607-1.195	0.353
Proximal colon	1.121	0.597-2.105	0.722
Distal colon	1.394	0.752-2.585	0.292
Rectum	0.682	0.374-1.245	0.213
pT stage	2.170	1.236-3.811	0.007
pN stage	2.204	1.185-4.099	0.013
pM stage	2.475	1.376-4.453	0.002
Neural invasion	1.317	0.655-2.648	0.440
Lymphovascular invasion	1.235	0.655-2.328	0.514
Pre-operative ileus	4.394	2.334-8.276	<0.001
Emergency operation	7.564	3.016-18.975	<0.001
Pathological stage (III-IV vs. I-II)	25.791	0.733-907.807	0.074
Surgical resection (palliative vs. radical)	2.308	1.223-4.356	0.010
Surgical type (open vs. laparoscopic)	2.428	1.345-4.382	0.003
Adjuvant chemotherapy	0.496	0.251-0.981	0.044

OS: Overall survival; SRCC: Signet-ring cell; HR: Hazard ratio; CI: Confidence interval; Pre-ALB: Pre-operative albumin; Pre-CEA: Pre-operative carcinoembryonic antigen; Pre-CA199: Pre-operative carbohydrate antigen 199

Establishment and evaluation of a nomogram prediction model

Based on the significant independent factors in the COX regression model, a nomogram was established for predicting OS in CRC patients with SRC component, as shown in Figure 3A. To determine the probability of survival, total score was obtained by summing up points for each variable. Patients with a higher total score were more likely to obtain a lower probability of 1-, 2-, and 3-year OS. The performance of the nomogram for OS prediction was bootstrapped and validated internally with a C-index of 0.800. The calibration plot for the probability of 3-year OS presented good agreement between predicted probability and actual observation (Figure 3B).

Each patient was scored and ranked according to percentiles, and afterward, risk classifications and stratifications were implemented to illustrate the ability of the nomogram to make risk assessments. The first 75% was identified as the cut-off value using the quartile spacing method, and the remainder was defined as high-risk and low-risk group. As shown in Figure 3C, patients in the low-risk group were likely to experience a better probability of OS ($p = 0.045$), in accordance with results from our nomogram.

In addition, the predictive value of our nomogram was compared with that of the 7th AJCC staging system by drawing a ROC curve and calculating AUC. The AUC of the nomogram was 0.829, significantly higher than 0.719 of the 7th AJCC staging system ($p < 0.001$). As illustrated in Figure 4, the nomogram showed superior OS predictive ability than the 7th AJCC staging system.

DISCUSSION

To date, only a few studies have focused on the clinical and prognostic value of the ratio of SRC components in colorectal

TABLE 3. Multivariate analysis of risk factors of OS in SRCC colorectal cancer

Variables	Adjusted HR	95%CI	<i>P</i> value
Pre-CEA (>5 ng/mL vs. ≤5 ng/mL)	3.286	1.584-6.819	0.001
Pre-ALB level	0.995	0.935-1.059	0.877
Tumor size	1.108	0.920-1.335	0.281
pT stage	1.435	0.693-2.973	0.331
pN stage	2.618	1.282-5.345	0.008
pM stage	2.804	1.165-6.747	0.021
Pre-operative ileus	5.457	2.142-13.900	<0.001
Emergency operation	1.612	0.403-6.447	0.499
Surgical resection (palliative vs. radical)	0.382	0.135-1.084	0.071
Surgical type (open vs. laparoscopic)	1.254	0.609-2.583	0.538
Adjuvant chemotherapy	0.153	0.064-0.362	0.000

OS: Overall survival; SRCC: Signet-ring cell; HR: Hazard ratio; CI: Confidence interval; Pre-ALB: Pre-operative albumin; Pre-CEA: Pre-operative carcinoembryonic antigen
P values in bold are significant




FIGURE 3. (A) Nomogram predicting the probability of 1-, 2-, and 3-year overall survival in SRCC colorectal cancer patients. (B) Calibration curves for 3- and 5-year disease-free survival in the internal validation cohort. (C) Overall survival between low-risk and high-risk groups. SRCC: Signet-ring cell carcinoma.




FIGURE 4. ROC curve for the nomogram prediction model and the AJCC 7th staging system. ROC: Receiver operating characteristic; AJCC: American Joint Committee on Cancer.

SRCC. In the present study, we demonstrated that colorectal SRCC with different SRC component has similar clinicopathological characteristics and comparable oncological outcome. After adjusting for potential confounding factors, the ratio of SRC component was not an independent prognostic factor of the OS. In addition, we developed a predictive nomogram for survival, which showed better performance than the 7th AJCC staging system.

In this study, the median age of CRC patients with different SRC components was 51, 46.5 in SRCC group and 57 in PSRCC group. It has been reported that colorectal SRCC is more likely to present at a younger age, which makes our results

consistent with the previous studies [8-10]. Similarly, colorectal SRCC was more likely to locate in the proximal colon and rectum, which was similar to the previous studies [7,10-13]. For PSRCC patients, most clinicopathological characteristics were similar to those for SRCC patients. Interestingly, we noted that patients in the SRCC group were more likely to experience pre-operative ileus, which turned out to be an independent prognostic factor. Unfortunately, no available studies exist regarding whether the ratio of SRC component is associated with pre-operative ileus. One possible explanation for absence of studies may be due to the relatively larger tumor size and diffusely infiltrated growth pattern of SRCC. In our cohort, the proportion of elevated pre-operative CEA and CA199 was not high, and this will probably underestimate pretreatment risk stratification of tumors. Extensive intraperitoneal dissemination was often encountered during the operation which increased rates of conversion from laparoscopic to open surgery. Our study suggested that the behavior pattern of PSRCC tumors might be similar to that of SRCC tumors.

It has been well documented that colorectal SRCC is associated with poor prognosis, with the 5-year survival rate ranging 0-37% [14-18]. Fu *et al.* [19] have demonstrated that the 5-year survival rate of resectable metastatic colorectal SRCC was 9.66%, which is significantly lower than that of normal adenocarcinoma and mucinous adenocarcinoma. In addition, molecular biological characteristics of colorectal SRCC were reported to be similar to those of standard SRCC [20]. There are inconclusive results regarding the prognostic value of the SRC ratio in colorectal SRCC. Inamura *et al.* [10] found that <50% of the SRC component was associated with a poorer prognosis and independent of other clinicopathological and tumor molecular characteristics. Tan *et al.* [7] have shown that

the prognosis of colorectal SRCC is poor regardless of the SRC component. Similarly, our results demonstrated that colorectal SRCC patients with different signet-ring cells components had similar OS. After adjustment for other confounding factors, the SRC ratio was not an independent predictor of the overall outcome.

Indeed, the molecular characterization may contribute to better understanding of SRCC. The previous studies demonstrate that colorectal SRCC exhibits features of aberrant DNA methylation [21]. Proximal colorectal SRCC is characterized by hypermethylated, with CpG island methylator phenotype, BRAF V600E mutation, and microsatellite instability [22]. On the other hand, distal colorectal SRCC is characterized by hypomethylated and upregulation of the epithelial-mesenchymal transition gene expression [22], all of which help to explain invasion and metastasis of tumor.

Similar to the previous studies, our study identified several independent prognostic factors of OS, including pre-operative CEA level, pN stage, M stage, pre-operative ileus, and adjuvant chemotherapy. Hugen *et al.* [11] have found that colorectal SRCC may benefit from adjuvant chemotherapy despite its dismal prognosis. In our study, the prognosis of patients with SRCC receiving adjuvant chemotherapy was better than those without adjuvant chemotherapy ($p < 0.038$). Univariate and multivariate analysis identified adjuvant chemotherapy as an independent risk factor for prognosis ($p < 0.001$). A high incidence of peritoneal dissemination has been noted in colorectal SRCC in clinical practice. At present, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is generally recommended as a treatment option for peritoneal carcinomatosis from digestive system cancers. Simken *et al.* [23] showed that SRCC is an adverse prognostic factor for intraperitoneal infusion chemotherapy (HR = 3.73, 95% CI 1.88-7.41) and that patients with peritoneal metastasis from CRC can benefit from intraperitoneal infusion chemotherapy. Unfortunately, the therapeutic effect and complications of CRS-HIPEC in our cohort could not be evaluated due to the lack of data.

Nomograms, as a new type of prediction tool, are currently widely used in clinical prediction for CRC patients [24-26]. We developed a predictive nomogram for OS in CRC with different SRC components by incorporating the five independent risk factors in the COX regression model. The prediction model enables us to generate an individualized prediction by a combination of five easy to obtained risk factors of colorectal SRCC in clinical practice. Moreover, we further evaluated the ability of the nomogram to make a risk assessment. The results showed that patients in the low-risk group were likely to experience a better probability of OS ($p = 0.045$). Therefore, our nomogram is helpful for clinicians to identify high-risk patients who are candidates for more intense follow-up and adjuvant therapy.

At present, the AJCC cancer staging system is the gold standard for predicting the prognosis of CRC patients [27,28]. Herein, we evaluated whether the AJCC staging system is effective in predicting the prognosis of CRC patients with different SRC components, as compared to our predictive nomogram. The results showed that the accuracy and predictive ability of our predictive nomogram were significantly better than those of the 7th AJCC staging system. Nevertheless, performance of our nomogram warrants further validation in larger population. There are several limitations in the present study. First, our study is a single-institutional retrospective study, which may be subject to selective bias. Second, due to the lack of adequate data, our study could not provide insight into the molecular and biological characteristics of CRC with different SRC components. Third, our study did not include clinical symptoms and physical status scores, and failed to evaluate the efficacy of different chemotherapy regimens. In addition, the prediction model is only validated internally due to relatively small sample size, and external validation in a large patient cohort is warranted. Despite these limitations, our study shed light into CRC with different SRC components in terms of clinicopathological characteristics and oncological outcome. To the best of our knowledge, for the 1st time, an individualized prognostic model was established for CRC patients with different SRC components in our study, and its predictive ability was significantly higher than that of the traditional AJCC staging system.

CONCLUSION

Our results demonstrated that colorectal SRCC has similar clinicopathological characteristics and comparable oncological outcome, despite the ratio of SRC components. After adjusting for potential confounding factors, ratio of SRC component was not an independent prognostic factor of the OS. Pre-operative CEA level, pN stage, M stage, pre-operative ileus, and adjuvant chemotherapy remained to be independent prognostic factors of OS. In addition, we developed a predictive nomogram for survival, which showed better performance than the 7th AJCC staging system.

Statement of ethics

This study was approved by the Medical Ethics Committee of our hospital.

REFERENCES

- [1] Laufman H, Saphir O. Primary linitis plastica type of carcinoma of the colon. *AMA Arch Surg* 1951;62(1):79-91. <https://doi.org/10.1001/archsurg.1951.01250030082009>.
- [2] Bosman FT, Carneiro F, Hruban RH, Theise ND. *WHO Classification of Tumours of the Digestive System*; 2010.

- [3] Mizushima T, Nomura M, Fujii M, Akamatsu H, Mizuno H, Tominaga H, et al. Primary colorectal signet-ring cell carcinoma: Clinicopathological features and postoperative survival. *Surg Today* 2010;40(3):234-8. <https://doi.org/10.1007/s00595-009-4057-y>.
- [4] Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, et al. Significance of signet-ring cells in patients with colorectal cancer. *Dis Colon Rectum* 2008;51(1):50-5. <https://doi.org/10.1007/s10350-007-9073-7>.
- [5] Psathakis D, Schiedeck TH, Krug F, Oevermann E, Kujath P, Bruch HP. Ordinary colorectal adenocarcinoma vs. primary colorectal signet-ring cell carcinoma: Study matched for age, gender, grade, and stage. *Dis Colon Rectum* 1999;42(12):1618-25. <https://doi.org/10.1007/bf02236218>.
- [6] Chen JS, Hsieh PS, Hung SY, Tang R, Tsai WS, Changchien CR, et al. Clinical significance of signet ring cell rectal carcinoma. *Int J Colorectal Dis* 2004;19(2):102-7. <https://doi.org/10.1007/s00384-003-0515-y>.
- [7] Tan Y, Fu J, Li X, Yang J, Jiang M, Ding K, et al. A minor (<50%) signet-ring cell component associated with poor prognosis in colorectal cancer patients: A 26-year retrospective study in China. *PLoS One* 2015;10(3):e0121944. <https://doi.org/10.1371/journal.pone.0121944>.
- [8] Bittorf B, Merkel S, Matzel KE, Wein A, Dimmler A, Hohenberger W. Primary signet-ring cell carcinoma of the colorectum. *Langenbecks Arch Surg* 2004;389(3):178-83. <https://doi.org/10.1007/s00423-004-0474-y>.
- [9] Chew MH, Yeo SE, Ng ZP, Lim KH, Koh PK, Ng KH, et al. Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2, 764 sporadic colorectal cancers. *Int J Colorectal Dis* 2010;25(10):1221-9. <https://doi.org/10.1007/s00384-010-1033-3>.
- [10] Inamura K, Yamauchi M, Nishihara R, Kim SA, Mima K, Sukawa Y, et al. Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. *Ann Surg Oncol* 2015;22(4):1226-35. <https://doi.org/10.1245/s10434-014-4159-7>.
- [11] Hugen N, Verhoeven RH, Lemmens VE, van Aart CJ, Elferink MA, Radema SA, et al. Colorectal signet-ring cell carcinoma: Benefit from adjuvant chemotherapy but a poor prognostic factor. *Int J Cancer* 2015;136(2):333-9. <https://doi.org/10.1002/ijc.28981>.
- [12] Nitsche U, Zimmermann A, Späth C, Müller T, Maak M, Schuster T, et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. *Ann Surg* 2013;258(5):775-82; discussion 782-3. <https://doi.org/10.1097/sla.0b013e3182a69f7e>.
- [13] Barresi V, Reggiani Bonetti L, Domati F, Baron L. Prognostic relevance of histopathological features in signet ring cell carcinoma of the colorectum. *Virchows Arch* 2016;469(3):267-75. <https://doi.org/10.1007/s00428-016-1983-0>.
- [14] Kang H, O'Connell JB, Maggard MA, Sack J, Ko CY. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. *Dis Colon Rectum* 2005;48(6):1161-8. <https://doi.org/10.1007/s10350-004-0932-1>.
- [15] Makino T, Tsujinaka T, Mishima H, Ikenaga M, Sawamura T, Nakamori S, et al. Primary signet-ring cell carcinoma of the colon and rectum: Report of eight cases and review of 154 Japanese cases. *Hepatogastroenterology* 2006;53(72):845-9.
- [16] Cai X, Qi WX, Wang L, Zhang Z. Correlation of multiple proteins with clinic-pathological features and its prognostic significance in colorectal cancer with signet-ring cell component. *Eur Rev Med Pharmacol Sci* 2016;20(16):3358-67.
- [17] Hynegstrom JR, Hu CY, Xing Y, You YN, Feig BW, Skibber JM, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: Analysis from the National cancer data base. *Ann Surg Oncol* 2012;19(9):2814-21. <https://doi.org/10.1245/s10434-012-2321-7>.
- [18] Lee WS, Chun HK, Lee WY, Yun SH, Cho YB, Yun HR, et al. Treatment outcomes in patients with signet ring cell carcinoma of the colorectum. *Am J Surg* 2007;194(3):294-8. <https://doi.org/10.1016/j.amjsurg.2006.12.041>.
- [19] Fu J, Wu L, Jiang M, Tan Y, Li D, Chen F, et al. Signet ring cell carcinoma of resectable metastatic colorectal cancer has rare surgical value. *J Surg Oncol* 2016;114(8):1004-8. <https://doi.org/10.1002/jso.24437>.
- [20] Xie L, Villeneuve PJ, Shaw A. Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: A population-based study in Canada. *Int J Oncol* 2009;34(4):1109-15. https://doi.org/10.3892/ijo_00000238.
- [21] Barresi V, Pedrazzani C. Colorectal signet ring cell carcinoma: Advancing research in a rare cancer. *Future Oncol* 2020;16(17):1161-3. <https://doi.org/10.2217/fon-2020-0242>.
- [22] Alvi MA, Loughrey MB, Dunne P, Mcquaid S, Turkington R, Fuchs MA, et al. Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. *Br J Cancer* 2017;117(2):203-9. <https://doi.org/10.1038/bjc.2017.168>.
- [23] Simkens GA, van Oudheusden TR, Nieboer D, Steyerberg EW, Rutten HJ, Luyer MD, et al. Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC. *Ann Surg Oncol* 2016;23(13):4214-21. <https://doi.org/10.1245/s10434-016-5211-6>.
- [24] Imai K, Allard MA, Benitez CC, Vibert E, Sa Cunha A, Cherqui D, et al. Nomogram for prediction of prognosis in patients with initially unresectable colorectal liver metastases. *Br J Surg* 2016;103(5):590-9. <https://doi.org/10.1002/bjs.10073>.
- [25] Kawai K, Nozawa H, Hata K, Kiyomatsu T, Tanaka T, Nishikawa T, et al. Nomogram predicting survival after recurrence in patients with stage I to III colon cancer: A nationwide multicenter study. *Dis Colon Rectum* 2018;61(9):1053-62. <https://doi.org/10.1097/dcr.0000000000001167>.
- [26] Mahar AL, Compton C, Halabi S, Hess KR, Weiser MR, Groome PA. Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes. *J Surg Oncol* 2017;116(8):969-82. <https://doi.org/10.1002/jso.24774>.
- [27] Chen VW, Hsieh MC, Charlton ME, Ruiz BA, Karlitz J, Altekruze SF, et al. Analysis of stage and clinical/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system. *Cancer* 2014;120 Suppl 23:3793-806. <https://doi.org/10.1002/cncr.29056>.
- [28] Kim KH, Yang SS, Yoon YS, Lim SB, Yu CS, Kim JC. Validation of the seventh edition of the American joint committee on cancer tumor-node-metastasis (AJCC TNM) staging in patients with stage II and stage III colorectal carcinoma: Analysis of 2511 cases from a medical Centre in Korea. *Colorectal Dis* 2011;13(8):e220-6. <https://doi.org/10.1111/j.1463-1318.2011.02625.x>.

Related articles published in BJBMS

1. The prognostic significance of different proportion of signet-ring cells of colorectal carcinoma
Wei Chen et al., BJBMS, 2020
2. Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with operable ampullary carcinoma
Nebi Serkan Demirci et al., BJBMS, 2018